CKPT (Checkpoint Therapeutics) Forward P/E Multiple
A stable geopolitical backdrop for biomedicine has driven share price growth, which is supported by Checkpoint Therapeutics (CKPT) forward P/E valuation, where the metric stands at 3.80. This positive momentum is based on Cosibelimab patents for high margins and a partnership with TG Therapeutics in therapy development. Such fundamental factors create a solid foundation for future cash flow and successful clinical trials.
Summary analytical data breakdowns for Checkpoint Therapeutics Inc (CKPT)
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Checkpoint Therapeutics|CKPT - Long-Term Liabilities to Capital|Short-Term Debt to Capital Checkpoint Therapeutics|CKPT - Company Total Debt|Debts to Book Capitalization Checkpoint Therapeutics Inc.|CKPT - Company Long-Term Loans and Borrowings|Company Short-Term Debts Checkpoint Therapeutics|Quick Ratio checkpointtx.com
- financial results and valuation multiples details:
CKPT - Net Income|Expected Profit Checkpoint Therapeutics|CKPT - P/E Multiple|Future Price to Earnings Checkpoint Therapeutics, Inc|CKPT - Market Cap to Earnings and Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Checkpoint Therapeutics Inc.|CKPT - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Checkpoint Therapeutics|CKPT - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months checkpointtx.com|CKPT - Earnings per share growth this year|Expected earnings per share growth for next year Checkpoint Therapeutics
Fundamental company analysis:Checkpoint Therapeutics, Inc.
Investors are evaluating the operating model of Checkpoint Therapeutics (CKPT) using a forward P/E ratio, which compares current market capitalization to expected earnings per share. By analyzing the company's forward P/E, one can determine the extent of the premium paid for cosibelimab's potential prior to FDA approval, where sharp deviations in the chart would indicate either unjustified optimism or the risk of business degradation.
Direct competitors
Projected Price to Earnings ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (RevMed)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Therapeutics (BCAX) - Future Price to Earnings|Personalis Inc - Future Price to Earnings Multiple|ERAS (Erasca Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Corp DCTH|Forward P/E Multiple YMAB|Projected Price to Earnings aurabiosciences.com AURA|Forward P/E Multiple CADL (Candel Therapeutics, Inc.)|Future Price to Earnings Multiple ARAY|SELLAS Life Sciences Group Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio Actuate Therapeutics Inc|CTOR: Forward P/E Multiple|Projected Price to Earnings TuHURA Biosciences|Future Price to Earnings Protara Therapeutics, Inc.|Forward P/E Multiple Fate Therapeutics Inc|Future Price to Earnings Aadi Bioscience Inc (WHWK)|TCRX: Price to Expected Earnings Ratio|Future Price to Earnings Champions Oncology, Inc. CSBR|XBiotech Inc (XBIT) - Projected Price to Earnings Ratio|CEL-SCI Corp - Forward P/E Multiple|Market Cap to Projected Earnings OS Therapies Inc. OSTX|Radiopharm Theranostics Limited (RADX) - Future Price to Earnings|Price to Future Earnings Ratio ARTV|Projected Price to Earnings ANL|VERU (verupharma.com) - Market Cap to Future Earnings Ratio|Projected Price to Earnings TPST (Tempest Therapeutics, Inc.)|XLO (xiliotx.com) - Future Price to Earnings Multiple|Renovaro - Projected Price to Earnings|Market Cap to Future Earnings Ratio MURA (Mural Oncology PLC)|Kairos Pharma Inc - Forward P/E Multiple|Future Price to Earnings Multiple OKUR (OnKure Therapeutics Inc)|GDTC: Forward P/E Multiple|Projected Price to Earnings Ratio Curis (CRIS)|Future Price to Earnings Apollomics Inc.|THAR: Future Price to Earnings Multiple|Forward P/E Multiple ADVB|Forward P/E Multiple genprex.com (GNPX)|Future Price to Earnings Calidi Biotherapeutics, Inc. CLDI|SBFM (Sunshine Biopharma Inc.) - Price to Expected Earnings Ratio|Xenetic Bio - Forward P/E Multiple|Projected Price to Earnings Ratio Salarius Pharma|PPBT (Purple Biotech) - Projected Price to Earnings|American Oncology Network, Inc. (AONC) - Forward P/E Multiple|Projected Price to Earnings BGNE|ELEV (elevationoncology.com) - Market Cap to Future Earnings Ratio|Forward P/E Multiple ICAD|Market Cap to Projected Earnings ikenaoncology.com|Forward P/E Multiple NTBL (Notable Labs, Ltd.)|VIRX - Projected Price to Earnings|MOR - Future Price to Earnings|Market Cap to Projected Earnings NAYA Biosciences Inc NAYA|AAPGV: Forward P/E Multiple
